Abstract

Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation

Author(s): Phan Ha, DeReese Annie, Day A J, Carvalho Maria

Issue: May/Jun 2014 - Volume 18, Number 3

Page(s): 203-207

Download in electronic PDF format for $75
  • Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation Page 1
  • Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation Page 2
  • Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation Page 3
  • Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation Page 4
  • Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation Page 5

Abstract

Domperidone is a prokinetic agent used as a second-line treatment option for gastroparesis in those unable to tolerate metoclopramide. Via inhibition of dopamine- 2 receptors within the gastrointestinal tract and various parts of the central and peripheral nervous system, domperidone helps to facilitate peristalsis and gastric emptying. A major side effect of domperidone is prolactinemia, allowing it to be used off-label for the purpose of inducing lactation. In the U.S., domperidone is currently not U.S. Food and Drug Administration approved due to various case reports and literature associating the risks of sudden cardiac death and ventricular arrhythmia with the use of domperidone. Despite the evidence against the use of domperidone, it is still being widely used in Canada and Europe for both gastroparesis and to induce milk let-down. This article is a literature review intending to assess the risks associated with the use of domperidone in gastroparesis and lactation.

Related Keywords

  • Ha Phan
  • domperidone
  • prokinetic agent
  • dopamine 2 receptors
  • prolactinemia
  • lactation induction
  • U.S. Food and Drug Administration
  • FDA
  • sudden cardiac death
  • arrhythmia
  • gastrointestinal motility
  • prolonged QTc interval
  • breast milk

Related Categories

  • GASTROENTEROLOGY
  • ADVERSE DRUG EVENTS
  • CARDIOLOGY
  • ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE
  • LITERATURE REVIEW

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2014
Pg. 203-207
Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation
Author(s): Phan Ha, DeReese Annie, Day A J, Carvalho Maria
Sep/Oct 2004
Pg. 329-335
Domperidone in Lactation: Use as a Galactagogue
Author(s): Albright Lisa M
Mar/Apr 2005
Pg. 120-125
View Sample
Use of Domperidone as a Prokinetic and Antiemetic
Author(s): Albright Lisa M
Jul/Aug 2016
Pg. 351
View Sample
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Author(s): Allen Loyd V Jr
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr
Jul/Aug 2019
Pg. 316
Domperidone 5 mg/mL in Oral Mix
Author(s): Allen Loyd V Jr
Jul/Aug 2015
Pg. 303-305
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Author(s): Miller David G
Jan/Feb 2019
Pg. 32-33
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Nov/Dec 2015
Pg. 487-488
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 296-297
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Author(s): Brunner Scott
Mar/Apr 2017
Pg. 95-102
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Author(s): Yoch Doug
May/Jun 2014
Pg. 208
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Author(s): Miller David G
Jul/Aug 2001
Pg. 310-312
Wetting and/or Solubilizing Agents, Featured Excipient:
Author(s): Allen Loyd V Jr
Jul/Aug 2007
Pg. 326-327
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration
Author(s): Kupiec Tom, Kemp Jesse
Nov/Dec 2021
Pg. 500
Domperidone 5 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Jan/Feb 2023
Pg. 22-23
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Author(s): Brunner Scott
Nov/Dec 2016
Pg. 457-458
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
Author(s):
Sep/Oct 2015
Pg. 389-390
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Author(s): Allen Loyd V Jr
Jan/Feb 2014
Pg. 35-36
U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013
Author(s): Miller David G
Nov/Dec 2023
Pg. 474-481
Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients
Author(s): Allen Loyd V Jr